Table 3.
Sensitivity and specificity of several D-dimer thresholds in PE-diagnosis in COVID-19 patients with respiratory symptoms.
| PE |
PE prevalence in COVID-19 patientsa |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| 5.6% |
21.2% |
||||||||
| Confirmed | Excluded | Total | Se | Sp | NPV | PPV | NPV | PPV | |
| D-dimer ≥ 500 ng/mL | |||||||||
| ≥500 | 46 | 91 | 137 | 100.0 | 9.0 | 100.0 | 6.2 | 100.0 | 22.8 |
| <500 | 0 | 9 | 9 | ||||||
| Total | 46 | 100 | 146 | ||||||
| D-dimer ≥ 1500 ng/mLb | |||||||||
| ≥1500 | 35 | 35 | 70 | 76.1 | 65.0 | 97.8 | 11.6 | 91.1 | 36.6 |
| <1500 | 11 | 65 | 76 | ||||||
| Total | 46 | 100 | 146 | ||||||
| D-dimer ≥ 2500 ng/mL | |||||||||
| ≥2500 | 23 | 16 | 39 | 50.0 | 84.0 | 96.5 | 15.9 | 86.3 | 45.4 |
| <2500 | 23 | 84 | 107 | ||||||
| Total | 46 | 100 | 146 | ||||||
| D-dimer ≥ 3500 ng/mL | |||||||||
| ≥3500 | 20 | 10 | 30 | 43.5 | 90.0 | 96.4 | 20.3 | 85.6 | 53.3 |
| <3500 | 26 | 90 | 116 | ||||||
| Total | 46 | 100 | 146 | ||||||
a
Two prevalences were tested considering prevalence of PE in our cohort (5.6%) and prevalence of PE in patients for whom it has been suspected (21.2%).
b
Optimal D-dimer according to the ROC curve. PE = pulmonary embolism; Se = sensitivity; Sp = specificity; NPV = negative predictive value; PPV = positive predictive value.